Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.820
-0.040 (-2.15%)
At close: Sep 12, 2025, 4:00 PM EDT
1.821
+0.001 (0.06%)
After-hours: Sep 12, 2025, 6:38 PM EDT
Pyxis Oncology Stock Forecast
Stock Price Forecast
The 4 analysts that cover Pyxis Oncology stock have a consensus rating of "Strong Buy" and an average price target of $7.75, which forecasts a 325.82% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $13.
Price Target: $7.75 (+325.82%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Pyxis Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 1 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 5 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Initiates $5 | Strong Buy | Initiates | $5 | +174.73% | Sep 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +174.73% | Aug 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +174.73% | May 19, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $8 | Buy | Reiterates | $8 | +339.56% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +174.73% | Mar 19, 2025 |
Financial Forecast
Revenue This Year
2.91M
from 16.15M
Decreased by -81.98%
Revenue Next Year
n/a
from 2.91M
EPS This Year
-1.33
from -1.32
EPS Next Year
-1.18
from -1.33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.2M | n/a | |||
| Avg | 2.9M | n/a | |||
| Low | 2.7M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -80.5% | - | |||
| Avg | -82.0% | - | |||
| Low | -83.0% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.28 | -0.82 | |||
| Avg | -1.33 | -1.18 | |||
| Low | -1.39 | -1.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.